

1Q11 Revenue Exceeds Expectations

TZ has provided an update of its 1Q11 trading results and current sales opportunities which are emerging. The company reported 1Q11 sales of US\$4.8 million, exceeding internal expectations by c16%, and that underlying operating costs were less than expected.

The PDT division (design and engineering outsourcing) continued its solid performance with sales exceeding expectations by 21% and margins steady. The strong 1Q11 result was predominantly driven by customers in the medical sector. TZ expects the robust demand to continue as a result of continued targeted sales and marketing efforts to customers in the healthcare, defence and consumer goods sectors.

The TZI division (commercialising TZ's IP) only achieved 79% of its revenue target due to delays in long lead-time electronic components deferring several booked order shipments into 2Q11. TZ indicated that the inventory stockouts were indicative of general low inventory levels globally and not specific to its components. It is worth noting that if orders booked during 1Q11 were able to be processed and delivered, the division would have exceeded its revenue target by 20%.

TZI's strong sales orders were driven by demand for Infrastructure Protection products substantially exceeding expectations. These products provide data centres with micro-security and audit capability at a data cabinet level. This helped to offset order delays in Packaged Asset Delivery (PAD) with several project timelines pushing out into late 2Q11. However, the company indicated that a substantially strong pipeline had emerged in PAD with one proposal under consideration having the potential to exceed the FY11 PAD revenue target on its own.

TZI has also started to increase its sales force with the addition of four new sales resources this month to substantially increase its US sales coverage and support sales generation in 2H11. The Infrastructure Protection business unit has also been actively engaged with Anixter sales resources in Latin America, Europe, Asia and Australia to drive a coordinated sales approach into these markets.

We expect positive sales updates and meeting FY11 guidance to be the key catalysts for gaining market credibility and being positively re-rated. Our 12-month price target is unchanged at \$0.84 per share which implies a market capitalisation of c\$60 million. We believe this is justified given the company has invested cUS\$30 million in IP and its products are now being globally launched by NYSE-listed partners. We are forecasting a 12-month return of 73% and maintain our Speculative Buy recommendation.

Year End June 30	2009A	2010A	2011F	2012F	2013F
Reported NPAT (\$m)	(25.7)	(21.2)	(8.3)	(4.1)	0.5
Recurrent NPAT (\$m)	(22.7)	(13.0)	(8.3)	(4.1)	0.5
Recurrent EPS (cents)	(46.8)	(24.5)	(9.3)	(3.7)	0.3
EPS Growth (%)	na	na	na	na	na
PER (x)	na	na	na	na	na
PEG	na	na	na	na	na
EBITDA (\$m)	(14.1)	(10.1)	(4.8)	(0.2)	4.4
EV/EBITDA (x)	(2.4)	(4.4)	(13.1)	(399.6)	15.1
Free Cashflow	(14.8)	(6.2)	(10.3)	(4.7)	0.4
FCFPS (cents)	(30.5)	(11.6)	(11.5)	(4.3)	0.3
PFCF (x)	na	na	na	na	na
DPS (cents)	0.0	0.0	0.0	0.0	0.0
Yield (%)	0.0	0.0	0.0	0.0	0.0
Franking (%)	0.0	0.0	0.0	0.0	0.0

1 November 2010

12mth Rating	SPECULATIVE BUY	
Price	A\$	0.485
Target Price	A\$	0.84
12m Total Return	%	73.1


RIC: TZL.AX	BBG: TZL AU	
Shares o/s	m	74.9
Free Float	%	80.0
Market Cap.	A\$m	36.3
Net Debt (Cash)	A\$m	18.6
Net Debt/Equity	%	819.0
3m Av. D. T'over	A\$m	0.03
52wk High/Low	A\$	0.98/0.27
2yr adj. beta		na

Valuation:

Methodology		DCF
Value per share	A\$	0.84

Analyst: Ben Kakoschke
Phone: (+61 3) 9242 4181
Email: bkakoschke@psl.com.au

12 Month Share Price Performance



Performance %	1mth	3mth	12mth
Absolute	55.0	72.2	-35.4
Rel. S&P/ASX 300	53.3	74.0	-29.7

TZ Limited					\$0.485					Year End June 30							
Profit and Loss (A\$m)					2010A	2011F	2012F	2013F	Valuation Data					2010A	2011F	2012F	2013F
Sales Revenue	17.6	25.4	41.5	56.4	Net profit adj (\$m)	-13.0	-8.3	-4.1	0.5								
EBITDA	-10.1	-4.8	-0.2	4.4	EPS (c)	-24.3	-9.3	-3.7	0.3								
D&A	-1.3	-1.6	-1.7	-1.7	P/E ratio (x)	n/a	n/a	n/a	n/a								
EBIT	-11.4	-6.4	-1.8	2.8	FCF per share (c)	-17.3	-10.4	n/a	n/a								
Net Interest Expense	-5.2	-1.9	-2.2	-2.3	Price/FCF (x)	n/a	n/a	n/a	n/a								
Pre-tax profit	-16.5	-8.3	-4.1	0.5	DPS (c) ordinary	0.0	0.0	0.0	0.0								
Tax	3.5	0.0	0.0	0.0	Franking (%)	n/a	n/a	n/a	n/a								
FX Translation Differences	0.1	0.0	0.0	0.0	Yield (%)	n/a	n/a	n/a	n/a								
Adj net profit	-13.0	-8.3	-4.1	0.5	EV/EBITDA (x)	n/a	n/a	-301.3	8.7								
Abnormals	-8.2	0.0	0.0	0.0	EV/EBIT (x)	n/a	n/a	n/a	13.8								
Reported Profit After Tax	-21.2	-8.3	-4.1	0.5	Net Debt/Equity (%)	819.0	799.5	222.9	12.2								
					Tax Rate (%)	21.1	0.0	0.0	0.0								
Adjusted NPAT from continuing operations and excludes abnormals																	
Cashflow (A\$m)					2010A	2011F	2012F	2013F	Profitability Ratios					2010A	2011F	2012F	2013F
EBIT	-11.4	-6.4	-1.8	2.8	EBITDA/Sales (%)	-57.4	-18.8	-0.4	7.9								
Depn and amortisation	1.3	1.6	1.7	1.7	EBIT/Sales (%)	-64.7	-25.3	-4.4	4.9								
Net Interest	-5.2	-1.9	-2.2	-2.3	Return on assets (%)	-25.0	-14.6	-5.7	0.6								
Tax paid	3.5	0.0	0.0	0.0	Return on equity (%)	-183.9	-353.4	-90.5	3.7								
(inc)/dec in wk'g cap	2.6	-2.6	-1.3	-0.7	Company Overview												
Other	3.3	0.0	0.0	0.0	TZ is a US-focused intellectual property and technology development company providing commercialisation of its own products as well as design and development for third parties.												
Operating cashflow	-5.9	-9.3	-3.7	1.4	The company's operations are divided into Telezygology, Inc. (TZI) and Product Development Technologies, Inc. (PDT). TZI leverages its IP creation and technology development to commercialise products which that help global enterprises protect, deliver and maintain critical assets. PDT uses its extensive design and engineering capabilities to deliver turn-key product development for third party products.												
Capex	-0.3	-1.0	-1.0	-1.0	TZ's major financial and operational restructuring in the past 12 months has been driven by current Board members Mark Bouris (Executive Chairman) and Kenneth Ting (Executive Director) who were appointed in June 2009. They have been instrumental in recapitalising the company and forming a clear strategy for the TZI division defined by target markets, customer needs and value proposition.												
Acquisitions/investments	0.0	0.0	0.0	0.0	Divisional Revenue (\$A)												
Other	0.0	0.0	0.0	0.0	Telezygology, Inc.												
Investing cashflow	-0.3	-1.0	-1.0	-1.0	Infrastructure Protection	n/a	4.4	15.9	25.4	Product Development Technologies, Inc.							
Equity raised	0.1	9.5	9.5	12.0	Packaged Asset Delivery	n/a	3.5	6.4	9.8	Total TZI Revenue	n/a	7.9	22.2	35.2			
Dividends paid	0.0	0.0	0.0	0.0	Total TZI EBITDA	n/a	-3.8	0.7	5.1	Total PDT Revenue	n/a	17.5	19.3	21.2			
Net change in borrowings	-0.5	5.6	4.7	-10.6	Total PDT EBITDA												
Other	6.4	0.0	0.0	0.0	Corporate	n/a	-3.0	-3.2	-3.3								
Financing cashflow	6.0	15.0	14.2	1.4	Total EBITDA	-10.1	-4.8	-0.2	4.4								
FX adjustments	-0.2	0.0	0.0	0.0	Valuation (\$A)												
Net change in cash	-0.3	4.8	9.5	1.8	TZI	0.88											
Balance Sheet (A\$m)					2010A	2011F	2012F	2013F	PDT	0.24							
Cash	0.2	5.0	14.5	16.3	Corporate & Other	-0.27											
Receivables	4.5	5.1	6.2	6.8	FY13 Net Debt*	-0.02											
Inventories - WIP	0.0	1.3	2.9	3.9	Valuation	0.84											
Other	0.0	0.0	0.0	0.0	* Following convertible note conversion in FY13												
Current assets	4.8	11.3	23.6	27.0													
Receivables	0.0	0.0	0.0	0.0													
Property Plant & Equipment	2.0	2.1	2.1	2.2													
Intangibles	25.0	23.9	22.8	21.8													
Deferred Tax Assets	2.4	2.4	2.4	2.4													
Other	0.0	0.0	0.0	0.0													
Non-current assets	29.4	28.4	27.4	26.4													
Total assets	34.2	39.7	51.0	53.4													
Accounts Payable	9.7	8.9	10.4	11.3													
Interest Bearing Liabilities	18.8	24.4	29.1	18.5													
Provisions	0.2	0.5	0.8	1.1													
Other	0.0	0.0	0.0	0.0													
Total current liabilities	28.7	33.8	40.3	30.9													
Interest Bearing Liabilities	0.0	0.0	0.0	0.0													
Provisions	0.6	1.0	1.7	2.3													
Deferred Tax Liabilities	2.5	2.5	2.5	2.5													
Other	0.0	0.0	0.0	0.0													
Total n.c. liabilities	3.2	3.5	4.2	4.8													
Total liabilities	31.9	37.3	44.5	35.6													
Shareholders funds	2.3	2.4	6.5	17.8													

Recommendation History



Date	Type	Target Price	Share Price	Recommendation	Return
06 Sep 10	Research Note	0.84	0.41	SB	
	Current Share Price		0.49		18.3%

Stock recommendations: Investment ratings are a function of Patersons expectation of total return (forecast price appreciation plus dividend yield) within the next 12 months. The investment ratings are Buy (expected total return of 10% or more), Hold (-10% to +10% total return) and Sell (> 10% negative total return). In addition we have a Speculative Buy rating covering higher risk stocks that may not be of investment grade due to low market capitalisation, high debt levels, or significant risks in the business model. Investment ratings are determined at the time of initiation of coverage, or a change in target price. At other times the expected total return may fall outside of these ranges because of price movements and/or volatility. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. This Document is not to be passed on to any third party without our prior written consent.

1300 582 256

patersons@psl.com.au

www.psl.com.au

Research

Alex Passmore – Head of Research	Phone: (+61 8) 9263 1239	Email: apassmore@psl.com.au
Andrew Quin – Research Strategy Coordinator	Phone: (+61 8) 9263 1152	Email: aquin@psl.com.au
Tony Farnham – Economist	Phone: (+61 2) 9258 8973	Email: tfarnham@psl.com.au

Resources

Edwin Bulseco – Oil & Gas Analyst	Phone: (+61 8) 9263 1660	Email: ebulseco@psl.com.au
Andrew Harrington – Coal Analyst	Phone: (+61 2) 8238 6214	Email: aharrington@psl.com.au
Michael Lovesey – Associate Analyst	Phone: (+61 8) 9263 1297	Email: mlovesey@psl.com.au
Scott Simpson – Senior Oil & Gas Analyst	Phone: (+61 8) 9263 1679	Email: ssimpson@psl.com.au
Simon Tonkin – Senior Resources Analyst	Phone: (+61 8) 9225 2816	Email: stonkin@psl.com.au
Gary Watson – Associate Analyst	Phone: (+61 8) 9263 1110	Email: gwatson@psl.com.au

Industrials

Graeme Carson – Industrial Analyst	Phone: (+61 3) 9242 4076	Email: gcarson@psl.com.au
Allan Franklin – Industrial Analyst	Phone: (+61 3) 9242 4001	Email: afranklin@psl.com.au
George Galanopoulos – Industrial Analyst	Phone: (+61 3) 9242 4172	Email: ggalanopoulos@psl.com.au
David Gibson – Industrial Analyst	Phone: (+61 8) 9263 1664	Email: dgibson@psl.com.au
Ben Kakoschke – Materials Analyst	Phone: (+61 3) 9242 4181	Email: bkakoschke@psl.com.au
Jonathan Kriska – REIT Analyst	Phone: (+61 2) 8238 6245	Email: jkriska@psl.com.au
Mark Simpson – Industrial Analyst	Phone: (+61 8) 9263 1678	Email: msimpson@psl.com.au
Russell Wright – Retail Analyst	Phone: (+61 2) 8238 6219	Email: rwright@psl.com.au

Quantitative

Mark Barsdell – Quantitative Analyst	Phone: (+61 3) 9242 4187	Email: mbarsdell@psl.com.au
Kien Trinh – Quantitative Analyst	Phone: (+61 3) 9242 4027	Email: ktrinh@psl.com.au

Institutional Dealing

Phil Schofield	Phone: (+61 2) 8238 6223	Email: pschofield@psl.com.au
Michael Brindal	Phone: (+61 2) 8238 6274	Email: mbrindal@psl.com.au
Gordon Anderson	Phone: (+61 2) 8238 6276	Email: ganderson@psl.com.au
Dan Bahen	Phone: (+61 8) 9263 1274	Email: dbahen@psl.com.au
Artie Damaa	Phone: (+61 2) 8238 6215	Email: adamaa@psl.com.au
Paul Doherty	Phone: (+61 3) 8803 0108	Email: pdoherty@psl.com.au
Trent Foxe	Phone: (+61 2) 8238 6265	Email: tfoxe@psl.com.au
Peter Graham	Phone: (+61 3) 9242 4129	Email: pgraham@psl.com.au
Chris Kelly	Phone: (+61 3) 9242 4078	Email: ckelly@psl.com.au
Ben McIlvrde	Phone: (+61 2) 8238 6253	Email: bmcilvrde@psl.com.au
Jeremy Nugara	Phone: (+61 3) 8803 0166	Email: jnugara@psl.com.au
Trevor Pike	Phone: (+61 3) 8803 0110	Email: tpike@psl.com.au
Sandy Wylie	Phone: (+61 8) 9263 1232	Email: swylie@psl.com.au

Important Notice: Copyright 2010. The contents contained in this report are owned by Patersons Securities Limited ('Patersons') and are protected by the Copyright Act 1968 and the copyright laws of other countries. The material contained in this report may not be copied, reproduced, republished, posted, transmitted or distributed in any way without prior written permission from Patersons. Modification of the materials or use of the materials for any other purpose is a violation of the copyrights and other proprietary rights of Patersons.

Disclaimer: Patersons believes that the information or advice (including any financial product advice) contained in this report has been obtained from sources that are accurate at the time of issue, but it has not independently checked or verified that information and as such does not warrant its accuracy or reliability. Except to the extent that liability cannot be excluded, Patersons accepts no liability or responsibility for any direct or indirect loss or damage caused by any error in or omission from this report. You should make and rely on your own independent inquiries.

If not specifically disclosed otherwise, investors should assume that Patersons is seeking or will seek corporate finance business from the companies disclosed in this report.

Warning: This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate to your particular investment objectives, financial situation or particular needs. Prior to making any investment decision, you should assess, or seek advice from your adviser, on whether any relevant part of this report is appropriate to your individual financial circumstances and investment objectives.

Disclosure: Patersons, its director and/or employees may earn brokerage, fees, commissions and other benefits as a result of a transaction arising from any advice mentioned in this report. Patersons as principal, its directors and/or employees and their associates may hold securities in the companies the subject of this report, as at the date of publication. These interests did not influence Patersons in giving the advice contained in this report. Details of any interests may be obtained from your adviser. Patersons as principal, its directors and/or employees and their associates may trade in these securities in a manner which may be contrary to recommendations given by an authorised representative of Patersons to clients. They may sell shares the subject of a general 'Buy' recommendation, or buy shares the subject of a general 'Sell' recommendation.

Stock recommendations: Investment ratings are a function of Patersons expectation of total return (forecast price appreciation plus dividend yield) within the next 12 months. The investment ratings are Buy (expected total return of 10% or more), Hold (-10% to +10% total return) and Sell (> 10% negative total return). In addition we have a Speculative Buy rating covering higher risk stocks that may not be of investment grade due to low market capitalisation, high debt levels, or significant risks in the business model. Investment ratings are determined at the time of initiation of coverage, or a change in target price. At other times the expected total return may fall outside of these ranges because of price movements and/or volatility. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. This Document is not to be passed on to any third party without our prior written consent.